The latest price target for Supernus Pharmaceuticals (NASDAQ:SUPN) was reported by Piper Sandler on September 11, 2024. The analyst firm set a price target for $36.00 expecting SUPN to rise to within 12 months (a possible 1.61% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ:SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals downgraded their neutral rating.

There is no last upgrade for Supernus Pharmaceuticals

The last downgrade for Supernus Pharmaceuticals Inc happened on September 11, 2024 when Piper Sandler changed their price target from $41 to $36 for Supernus Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on September 11, 2024 so you should expect the next rating to be made available sometime around September 11, 2025.

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a downgraded with a price target of $41.00 to $36.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $35.43, which is out of the analyst’s predicted range.